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Background/aim: Galanin is a neuropeptide that is shown to be involved in the regulation of food intake and glucose homeostasis. The
objective of this study was to evaluate the relation of serum galanin levels with anthropometric and metabolic parameters in obese and
healthy children.
Material and methods: The cross-sectional study consisted of 38 obese children (mean age: 11.9 ± 3.0 years) and 30 healthy children
(mean age: 11.4 ± 2.0 years). Clinical and biochemical parameters [glucose, insulin, homeostasis model assessment-insulin resistance
(HOMA-IR), lipids, galanin, and leptin levels] were assessed.
Results: Serum galanin and leptin levels were significantly higher in obese children. In obese children, galanin levels were positively
correlated with fasting glucose (r = 0.398, p = 0.013), insulin (r = 0.383, p = 0.018), HOMA-IR (r = 0.375, p = 0.020), and triglycerides
(r = 0.391, p=0.015). Multivariate backward regression analysis revealed that galanin levels were significantly associated with fasting
glucose, insulin, HOMA-IR, and triglyceride, which explained 42.0% of the variance (r2 = 0.483, P < 0.001).
Conclusions: Serum galanin levels were significantly higher in obese children than healthy controls and positively correlated with
insulin resistance and triglycerides in obese children. This study suggests that galanin is associated with glucose homeostasis and lipid
metabolism in childhood obesity.
Key words: Childhood obesity, galanin, glucose homeostasis, insulin resistance, leptin

1. Introduction
Obesity, with a worldwide increasing prevalence, is an
important health problem that causes significant mortality
and morbidity (1). It is a complex condition that is mostly
caused by an imbalance between food intake and energy
expenditure as well as sedentary lifestyle (1). Recent
studies have shown that appetite is regulated by a complex
network of peptides that are synthesized in the peripheral
and central nerve system (2,3). Most peptides mediate
their effects in hypothalamus, leading to stimulation or
inhibition of food intake (1–3).
Galanin, a 29/30 amino acid peptide, was first identified
in 1983 from the porcine intestine by Tatemoto et al. (4).
Galanin is synthesized in several tissues including the
central and peripheral nervous systems and is believed
to be involved in the regulation of eating behavior.
Increased galanin concentration stimulates food intake
and increases the risk of obesity via activating galanin
receptor 1 (GalR1), one of the three receptors of galanin,
* Correspondence: ayhanabaci@gmail.com
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that is mainly distributed in the hypothalamus (5–9). On
the other hand, food consumption was demonstrated to be
decreased in galanin knockout mice and in rats that were
given intracerebroventricular galanin antagonist (M40 and
C7 molecules) (10,11). Higher concentrations of plasma
galanin have been found in adult patients with obesity,
impaired glucose tolerance, type 2 diabetes mellitus,
and gestational diabetes mellitus (8,12–15). In addition,
serum galanin levels are lower in lean women than normal
controls, suggesting that galanin concentrations are
higher in subjects with greater amounts of adipose tissue
(16). Moreover, a limited number of studies investigating
galanin concentrations have been conducted in children
with type 1 diabetes and epilepsy receiving valproate, and
significantly higher concentrations of galanin than in
healthy subjects were demonstrated (17,18). Some studies
have indicated that the galanin neuropeptide contributes
to the regulation of glucose and insulin homeostasis by
increasing insulin sensitivity (5,6,15,19,20). To the best
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of our knowledge, no prior study has investigated the
relationship between galanin levels and childhood obesity.
The aim of this study was to evaluate the levels of galanin
and its relation with anthropometric and metabolic
parameters in obese children.
2. Materials and methods
The current study consisted of 38 obese children with a
current body mass index (BMI) greater than or equal to
the 95th percentile, according to the Centers for Disease
Control and Prevention (CDC-2000), and 30 age- and sexmatched healthy children with a BMI between the 3rd and
85th percentiles. The BMI of each case was calculated by
dividing weight in kilograms by height in squared meters.
For calculation of percentiles and standard deviation
scores (SDSs) of all anthropometrics according to CDC
data, the Child Metrics online calculator program (http://
www.childmetrics.com) was used (21,22).
A comprehensive physical examination was
performed for all subjects, including both the obese and
control subjects, before the outset of the current study.
Children with any acute infection, chronic systemic
diseases (respiratory, neurologic, cardiovascular, or
gastrointestinal), a history of drug use (antiepileptics,
antipsychotics, and steroids), endocrinological disease
(hypothyroidism or Cushing syndrome), or suspected
obesity-related syndromes (Prader–Willi, Bardet–Biedl,
and Alstrom syndromes) were excluded from the current
study.
A Harpenden stadiometer with sensitivity of 0.1
cm was used for measurement of height. Body weight
measurement was performed using a scale with sensitivity
of 0.1 kg (SECA, Hamburg, Germany). BMI was calculated
by dividing weight in kilograms by height in square
meters. The body weight of each participant was measured
while wearing light clothing. Waist circumference (WC)
was measured using a nonstretchable tape between the
midpoint of the lowest rib cage and the iliac crest without
clothing, to the nearest 0.1 cm, at the end of a gentle
expiration (23). WC SDS was calculated according to the
data for Turkish children (24). Bioelectrical impedance
analysis (Tanita BC-418, Tokyo, Japan) was used for
measuring percent body fat (PBF) and fat mass (kg) in all
subjects.
Pubertal development of each participant was assessed
according to Tanner’s staging (25). Testicular volume of ≥4
mL in boys and breast development of stage 2 and above in
girls were considered as pubertal findings.
The homeostasis model assessment of insulin resistance
(HOMA-IR) index was used to assess the status of insulin
resistance. Different cut-off values according to pubertal
phases were employed to define the insulin resistance
status (prepubertal >2.5, pubertal >4.0) (26).

Blood pressure measurements were performed using
a calibrated sphygmomanometer by the same investigator
using a validated protocol. Systolic blood pressure (SBP)
and diastolic blood pressure (DBP) were measured twice
on the right arm after 10 min of rest in the supine position.
This study was approved by the ethical committee of
the Dokuz Eylül University School of Medicine in İzmir,
Turkey, in accordance with the Declaration of Helsinki.
All of the children and their parents gave their written
informed consent before the study.
Blood samples for analyzing glucose, lipid profile,
insulin, galanin, and leptin levels were taken after 10–12
h of overnight fasting. Venous blood samples were taken
in the morning and centrifuged at 1200 × g 10 min, and
the serum samples were collected into Eppendorf tubes
using plastic Pasteur pipettes and they were stored at
–80 °C until analysis. Fasting serum glucose, triglyceride
(TG), total cholesterol (TC), and high-density lipoprotein
(HDL-C) levels were measured enzymatically using the DP
Modular Systems (Roche Diagnostic Corp., Indianapolis,
IN, USA). Low-density lipoprotein cholesterol (LDL-C)
levels were calculated using the Friedewald formula
when plasma TG levels were <400 mg/dL. Serum insulin
levels were measured by electrochemiluminescence
immunoassay method using an automated immunoassay
analyzer (Immulite 2500 Insulin, Diagnostic Products
Corporation, Los Angeles, CA, USA). Serum galanin
(Cat No.: S-1347, Peninsula Laboratories, San Carlos,
CA, USA) and leptin (Cat No.: EK0437, Boster Biological
Technology Co. Ltd., Wuhan, China) were measured by
an enzyme-linked immunosorbent assay (ELISA) kit
based on the principle of sandwich enzyme immunoassay.
The microplate in the kit is precoated with an antibody
specific to the analyte. The standard is reconstituted and
prepared by serial dilution with the sample diluent. Serum
samples are diluted with sample diluent at ratios of 1:10
for leptin and 1:1 for galanin assays. The ELISA tests for
galanin and leptin respectively had a sensitivity of 0.022
ng/mL and <10 pg/mL, a detection range of 0.313–10 ng/
mL and 0.625–40 ng/mL, and intraassay CV of <10% and
interassay CV of <15%.
Statistical analyses of the data were performed
using SPSS 20.0 for Windows (IBM Corp., Armonk,
NY, USA). Distribution of data was evaluated using the
Kolmogorov–Smirnov test. For numerical comparisons,
Student’s t-test or Mann–Whitney U- tests were used to
assess differences between two groups according to the
normal distribution of the measured parameters. The chisquare test was used to compare the categorical variables.
Spearman’s rho correlation was used to identify the
associations between variables. Variables with a P-value
of <0.05 in bivariate correlation analysis were included
in the multivariate linear regression analysis model to
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evaluate the independent determinants of serum galanin
levels. Data were presented as mean ± standard deviation
(SD) or median and interquartile range (IQR, 25th–75th
percentile). In all statistical tests, P < 0.05 was considered
as statistically significant.

< 0.001) were significantly associated with fasting glucose
(β-coefficient = 0.478, P = 0.003), insulin (β-coefficient =
2.319, P = 0.001), HOMA-IR (β-coefficient = –2.255, P =
0.002), and TG (β-coefficient = 0.382, P = 0.005), which
explained 42.0% of the variance (Table 5).

3. Results
The present study included 38 obese children (mean age:
11.9 ± 3.0 years) and 30 healthy children (mean age: 11.4
± 2.0 years). The clinical, anthropometric, and laboratory
characteristics are shown in Tables 1 and 2. There was
no significant difference between the two groups in
terms of age, sex, and pubertal status (Table 1). However,
signiﬁcant differences were found between obese and
healthy children regarding BMI, BMI-SDS, WC, WC SDS,
fat mass, PBF, HOMA-IR, SBP, DBP, serum insulin, TG,
TC, LDL-C, HDL-C, leptin, and galanin levels (Tables 1
and 2). Additionally, age, pubertal status, WC, BMI, fat
mass, HOMA-IR, insulin, and TG levels were significantly
different among subjects with and without insulin
resistance (Table 3).
In the obese children, galanin was positively correlated
with fasting glucose (r = 0.398, p = 0.013), insulin (r =
0.383, p = 0.018), HOMA-IR (r = 0.375, p = 0.020), and
TG (r = 0.391, p = 0.015) (Table 4; Figures 1 and 2). On
the other hand, no such correlation was found between
galanin levels and anthropometric and metabolic
parameters. Multivariate backward regression analysis in
obese children revealed that galanin levels (r2 = 0.483, P

4. Discussion
In the present study, in which serum galanin levels were
investigated in obese children for the first time, significantly
higher levels of galanin were found in obese children than
in healthy children. These results are consistent with the
previous studies conducted in adults (12,16,20,27). Studies
conducted by Baranowska et al. (12,16) showed higher
serum galanin levels in obese women, especially in those
with BMI >31, than in healthy controls. In these studies,
increased serum galanin levels were found to be associated
with increased BMI and adipose tissue. In a study
conducted by Meczekalski et al. (27), significantly higher
levels of serum galanin were observed in adult obese
women compared to controls. In another study, serum
galanin levels in nondiabetic adult obese male subjects
were reported to be significantly higher at baseline and
during the oral glucose tolerance test (OGTT) compared to
healthy controls (20). The results of our study extend these
finding by indicating that galanin levels are associated with
obesity in children and adolescents as well.
Several studies investigating the effects of galanin
peptide on insulin and glucose metabolism have reported
that galanin enhances insulin sensitivity and increases

Table 1. The clinical characteristics of obese and healthy children.
Obese children (n = 38)

Healthy children (n = 30)

P

Age (years)

11.9 ± 3.0

11.4 ± 2.0

0.404a

Sex (male/female)

24/14

18/12

0.790c

Pubertal/prepubertal

20/18

19/11

0.376c

BMI (kg/m2)

31.3 ± 5.2

18.8 ± 2.2

<0.001a

BMI SDS

2.3 ± 0.2

0.04 ± 0.7

<0.001a

WC (cm)

101.3 ± 12.6

66.8 ± 9.5

<0.001a

WC SDS

3.78 ± 0.55

0.54 ± 0.65

<0.001a

Fat mass (kg)

28.8 (22.1–39.1)

6.4 (5.3–13.2)

<0.001b

PBF (%)

38.7 ± 5.2

18.6 ± 5.0

<0.001a

SBP (mmHg)

115 (110–125)

100 (95–110)

<0.001 b

DBP (mmHg)

70 (70–80)

60 (55–66.3)

<0.001b

Student’s t-test, bMann–Whitney U test, cchi-square test; data are given as mean ± SD or median (IQR 25th–
75th percentile).
BMI: Body mass index, BMI-SDS: standard deviation score of body mass index, WC: waist circumference, WC
SDS: standard deviation score of waist circumference, PBF: percent of body fat, SBP: systolic blood pressure,
DBP: diastolic blood pressure.

a
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Table 2. The laboratory characteristics of obese and healthy children.
Obese children
(n = 38)

Healthy children
(n = 30)

P

Glucose (mg/dL)

84.3 ± 5.4

83.8 ± 4.8

0.819a

Insulin (µIU/mL)

17.1 (10.9–23.6)

5.4 (3.4–10.4)

<0.001b

HOMA-IR

3.4 (2.1–5.7)

1.1 (0.7–1.5)

<0.001b

TG (mg/dL)

112.0 (96.8–165.0)

64.0 (53.0–86.5)

<0.001b

TC (mg/dL)

165.0 (151.7.5–193.5)

154.0 (138.8–163.3)

0.001b

LDL-C (mg/dL)

97.5 (89.5–117.3)

87.0 (75.5–97.5)

0.002b

HDL-C (mg/dL)

46.1 ± 8.1

59.4 ± 12.5

<0.001a

Galanin (ng/mL)

1.12 (0.93–1.37)

0.98 (0.85–1.11)

0.010b

Leptin (ng/mL)

10.1 (4.3–13.7)

1.2 (0.8–3.5)

<0.001b

Student’s t-test, bMann–Whitney U test; data are given as mean ± SD or median (IQR 25th–75th percentile).
HOMA-IR: Homeostasis model assessment-insulin resistance, TG: triglyceride, TC: total cholesterol, LDL-C:
low-density lipoprotein cholesterol, HDL-C: high-density lipoprotein cholesterol.

a

Table 3. The clinical and laboratory characteristics of obese patients with and without insulin resistance.
IR (-) group (n = 14)

IR (+) group (n = 24)

P

Age (years)

10.3 (8.9–12.2)

13.1 (10.4–14.8)

0.016a

Sex (male/female)

10/4

14/10

0.700b

Pubertal/prepubertal

3/11

17/7

0.001b

BMI (kg/m2)

28.7 (25.8–30.3)

32.2 (29.7–35.4)

0.002a

BMI SDS

2.3 ± 0.2

2.4 ± 0.2

0.117c

WC (cm)

93.5 (84.8–102.3)

105.2 (97.7–113.0)

0.006a

WC SDS

3.5 (2.9–4.2)

4.0 (3.5–4.2)

0.058a

Fat mass (kg)

23.8 ± 7.5

35.0 ± 11.9

0.003c

PBF (%)

36.7 ± 4.4

39.9 ±5.4

0.073c

Glucose (mg/dL)

79.5 (75.5–91.0)

86.5 (84.2–92.5)

0.071a

Insulin (µIU/mL)

8.1 (6.9–11.1)

22.6 (16.7–31.5)

<0.001a

HOMA-IR

1.6 (1.4–2.2)

5.1 (3.5–6.3)

<0.001a

TG (mg/dL)

100 (89.3–105)

135.5 (108.3–198.8)

0.004a

TC (mg/dL)

154.5 (150–169.3)

178.5 (153.8–195.0)

0.062a

LDL-C (mg/dL)

95 (86.5–100.8)

102 (92.3–124.8)

0.106a

HDL-C (mg/dL)

47 (39–56.3)

44.5 (38.3–52.3)

0.410a

Galanin (ng/mL)

0.95 ± 0.4

1.27 ± 0.4

0.228c

Leptin (ng/mL)

10.9 (2.6–14.19)

8.98 (5.3–12.8)

0.893a

a
Mann–Whitney U test, bchi-square test, cStudent’s t-test; data are given as median (IQR 25th–75th percentile).
IR: Insulin resistance, BMI: body mass index, BMI-SDS: standard deviation score of body mass index, WC:
waist circumference, WC-SDS: standard deviation score of waist circumference, PBF: percentage of body fat,
HOMA-IR: homeostasis model assessment-insulin resistance, TG: triglyceride, TC: total cholesterol, LDL-C:
low-density lipoprotein cholesterol, HDL-C: high-density lipoprotein-cholesterol.
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Table 4. Correlation coefficients between galanin levels and anthropometric and laboratory
parameters.
Parameters

Obese children (n = 38)

Healthy children (n = 30)

r*

P

r*

P

Age (years)

0.169

0.310

0.134

0.479

BMI (kg/m )

0.160

0.337

0.141

0.458

BMI SDS

0.103

0.537

0.115

0.545

WC (cm)

0.116

0.487

0.168

0.374

WC SDS

–0.124

0.457

0.069

0.716

Fat mass (kg)

0.138

0.339

–0.004

0.981

PBF (%)

0.191

0.318

–0.153

0.345

SBP (mmHg)

0.202

0.312

–0.092

0.683

DBP (mmHg)

0.208

0.226

–0.011

0.960

Glucose (mg/dL)

0.398

0.013

0.088

0.644

Insulin (µIU/mL)

0.383

0.018

–0.110

0.564

HOMA-IR

0.375

0.020

–0.024

0.901

TG (mg/dL)

0.391

0.015

–0.074

0.699

TC (mg/dL)

0.218

0.183

0.068

0.690

LDL-C (mg/dL)

0.229

0.166

–0.045

0.812

HDL-C (mg/dL)

0.025

0.879

0.243

0.196

Leptin (pg/mL)

–0.061

0.715

–0.182

0.335

2

*Spearman’s correlation analysis; serum galanin level as dependent variable.
BMI: Body mass index, BMI-SDS: standard deviation score of body mass index, WC:
waist circumference, WC SDS: standard deviation score of waist circumference, PBF:
percent of body fat, SBP: systolic blood pressure, DBP: diastolic blood pressure, HOMAIR: homeostasis model assessment-insulin resistance, TG: triglyceride, TC: total cholesterol,
LDL-C: low-density lipoprotein cholesterol, HDL-C: high-density lipoprotein cholesterol.

Figure 1. The positive correlations of galanin levels with fasting glucose (A) and insulin (B) in obese children.
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Figure 2. The positive correlations of galanin levels with HOMA-IR (A) and triglyceride (B) in obese children.

Table 5. Multivariate backward linear regression analysis.
Variable

B (95% CI)

SRC (β)

t

P-value

Glucose (mg/dL)

0.021 (0.007 / 0.034)

0.478

3.028

0.003

Insulin (µIU/mL)

0.059 (0.026 / 0.093)

2.319

3.579

0.001

HOMA-IR

–0.229 (–0.0367 / –0.091)

–2.255

–3.369

0.002

TG

0.005 (0.002 / 0.009)

0.382

3.028

0.005

HOMA-IR: Homeostasis model assessment-insulin resistance, TG: triglyceride, B: coefficient of regression,
SRC: standardized regression coefficient (r2 = 0.483, P < 0.001, Durbin–Watson = 1.922).

glucose uptake (5,6,20,27,28). Similarly, OGTT and
hyperinsulinemic-euglycemic clamp studies demonstrated
that galanin knockout mice and galanin antagonist (M35)administered rats exhibited impaired glucose metabolism
and increased insulin resistance, whereas increased insulin
sensitivity was shown in transgenic mouse models (5,28–
32). Bu et al. (33) showed that galanin administration
in rats increases glucose utilization via activation of
GLUT4, which is significantly expressed in fat and muscle
tissue. On the other hand, administration of the galanin
antagonist (M35) decreased GLUT4 channel expression
and affected insulin-glucose metabolism (5,34). In other
studies in adults with impaired glucose tolerance, type
2 diabetes, and gestational diabetes mellitus, serum
galanin levels were reported to be significantly higher
compared to healthy controls and correlated positively
with glucose levels (13,14). Moreover, Sandoval-Alzate
et al. (20) reported a positive correlation between serum
galanin levels and HOMA-IR, BMI, and insulin levels at
all OGTT time points and with glucose levels at 60- and
120-min time points of the OGTT in nondiabetic obese

adults. Similarly, in the present study, serum galanin levels
were significantly correlated with fasting glucose, fasting
insulin, and HOMA-IR in obese subjects, which seems to
be conflicting with the positive effect of galanin on glucose
metabolism. This can be explained by the galanin receptor
resistance due to impairment in the galanin system, which
helps in maintaining the glucose level within the normal
range, similar to the role of insulin or leptin resistance in
obesity (13,35). Furthermore, one study also noted that
there may be an association between insulin resistance
and galanin resistance in obesity (35). In line with this
hypothesis, a positive correlation was also demonstrated
between serum galanin levels and HOMA-IR in the present
study. Additionally, in our study, serum galanin levels in
obese subjects with insulin resistance were higher than
in those without insulin resistance (1.27 vs. 0.95 ng/mL);
however, statistical significance could not be determined
due to a low number of subjects in subgroup analyses.
Some studies have demonstrated that serum galanin
levels are closely associated with increased fat consumption
and serum TG levels (5,10,19,20,36–39). Significantly
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higher fat-rich food consumption was observed in mice
after an injection of galanin into the paraventricular nucleus
or in galanin transgenic mice that led to overexpression of
galanin (10,37). Additionally, it is well known that there
is a close relationship between high-fat diet and serum
TG (36). Taken together, it is noteworthy to say that there
may be a close relation between the serum TG level and
the galanin peptide, which increases the intake of fat-rich
food. Poritsanos et al. (8) reported that TC and TG levels
were significantly increased in transgenic mice that have
10-fold excess of galanin. Similarly, a positive association
was demonstrated between serum galanin and TG levels
in adult obese subjects by Fang et al. (19,38) and between
serum galanin and TG and TC in nondiabetic obese
adults by Sandoval-Alzate et a (20). In the present study,
likewise, a positive correlation between serum galanin
and TG levels was shown. This relationship suggests
that galanin peptide, which causes an increase in food
consumption, contributes to the development of obesity
and its related effects, such as dyslipidemia. On the other
hand, there are studies showing that a high-fat diet may
cause changes in serum galanin levels (36,40). Leibowitz
et al. (40) showed a 40% increase in galanin levels in the
hypothalamus of high-fat-fed mice. In the same study, it
was also reported that the level of TG in the hypothalamus
was positively correlated with the mRNA transcript level
of galanin; thus, the authors proposed that galanin levels
may have increased in response to elevated serum TG.
Taken together, these findings show that serum TG levels
and galanin in obese subjects can be affected by nutrient
contents such as fat. However, since the dietary habits of
the patients were not taken into consideration, the effect
of the nutritional pattern on galanin and TG were not
investigated in the present study.
Another metabolic parameter that was evaluated in this
study is leptin, which is mainly synthesized in the adipose
tissue and inhibits food intake, contrary to galanin, which
has an orexigenic effect (6,41). In experimental studies,
a close association between ghrelin and leptin levels in
the hypothalamus has been demonstrated (42). Leptin
administration has been shown to reduce food intake and
cause weight loss by reducing the expression of galanin
in the hypothalamus, especially in the paraventricular
nucleus (43,44). Moreover, it has been suggested that
galanin exerts its effect on feeding behavior by inhibiting
the effect of leptin (42,44). Moreover, galanin-knockout
mice were reported to have higher leptin levels and
increased leptin sensitivity, which in turn results in greater
weight loss (42,45). Findings of another study indicated
that these two hormones are involved in a common
molecular interplay in the hypothalamus and that they
modulate the effect of each other on feeding behavior
(46). There is only one clinical study that has examined
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the relationship between serum galanin and leptin levels
in obese subjects. Sandoval-Alzate et al. (20) reported a
positive relationship between serum galanin and leptin
levels in nondiabetic adults. However, in this study, obese
and healthy subjects were evaluated together when the
correlation was made, and that could have contributed
to the positive relationship between serum galanin and
leptin levels. In the present study, serum leptin and
galanin levels were found to be significantly higher in
obese subjects, but no relationship was found between
them. There is a need for advanced molecular studies that
can uncover the complex relationship between these two
hormones, which interact with each other and modulate
their effect on feeding behavior.
This study has some limitations. Even though higher
serum galanin levels were found in obese subjects with
insulin resistance than those without insulin resistance,
this difference was not statistically significant due to
the low number of subjects. Although we demonstrated
significant associations regarding galanin in obese
subjects, the sample size was not calculated before
initiating the study and therefore we could not evaluate
the effect of sample size on study results. In addition,
subjects with probable type 2 diabetes or impaired
glucose tolerance among obese subjects with insulin
resistance could not be excluded as OGTT was not done.
Furthermore, while clamp studies are regarded as the
gold standard for determining insulin resistance, we used
the HOMA model instead. However, a validation study
demonstrated a strong association between HOMA and
clamp techniques in young subjects; therefore, the HOMA
model can be used to evaluate insulin resistance. (46).
Lastly, we did not evaluate the dietary habits of subjects
and therefore the relation of nutrition type with galanin
could not be investigated.
In conclusion, the current study demonstrated that the
serum galanin levels in obese children were significantly
higher than in healthy controls and that galanin and TG
levels are positively correlated. These findings suggest a
role of galanin, an orexigenic peptide, in the development
of obesity and related metabolic disorders. In addition, in
obese subjects, serum galanin levels were demonstrated
to be positively correlated with fasting insulin, fasting
glucose, and HOMA-IR. The increase in galanin, which
is known to have a regulatory role in insulin and glucose
metabolism, could indicate a compensatory increase
to increase insulin sensitivity in obese individuals with
insulin resistance or an occurrence of galanin resistance
in tissue, similar to leptin and insulin resistance. Further
molecular studies to further study the concept of
galanin resistance in obese subjects will provide a better
understanding of the effect of galanin on insulin and
glucose metabolism.
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